The probability of side effects with ovral, norinyl 1/50 and norlestrin.
This report provides specific information on the prevalence rates of the most common side effects during the first 3 cycles of use of 3 combination oral contraceptives (OCs) containing 50 mcg estrogen. The probabilities of a symptom occurring for the first time, or persisting once present, during the initial cycles of OC use are given for each of the 3 combined OCs.
D000152:Acne Vulgaris / Q000139:chemically induced; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008598:Menstruation; D008656:Mestranol / Q000009:adverse effects*; D009640:Norethindrone / Q000009:adverse effects*; D009644:Norgestrel / Q000009:adverse effects*; D011336:Probability; D013997:Time Factors; D014592:Uterine Hemorrhage / Q000139:chemically induced
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D009644:Norgestrel; D004997:Ethinyl Estradiol; D008656:Mestranol; D009640:Norethindrone